PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-6.56%
R&D reduction while TRAW shows 20.61% growth. Joel Greenblatt would examine competitive risk.
-79.23%
G&A reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
-99.88%
Other expenses reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine efficiency.
-74.55%
Operating expenses reduction while TRAW shows 21.30% growth. Joel Greenblatt would examine advantage.
-74.55%
Total costs reduction while TRAW shows 21.30% growth. Joel Greenblatt would examine advantage.
-99.95%
Interest expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
609.47%
D&A growth above 1.5x TRAW's 12.64%. Michael Burry would check for excessive investment.
90.56%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
74.50%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
136.63%
Other expenses growth 50-75% of TRAW's 227.91%. Bruce Berkowitz would examine cost efficiency.
91.74%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-502.21%
Tax expense reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine advantage.
91.74%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
91.71%
EPS change of 91.71% while TRAW is flat. Bruce Berkowitz would examine quality.
91.71%
Diluted EPS change of 91.71% while TRAW is flat. Bruce Berkowitz would examine quality.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.